124 related articles for article (PubMed ID: 38112005)
1. Cognitive dysfunction following finasteride use: a disproportionality analysis of the global pharmacovigilance database.
Cho Y; Bea S; Bae JH; Kim DH; Lee JH; Shin JY
Expert Opin Drug Saf; 2023 Dec; ():1-7. PubMed ID: 38112005
[TBL] [Abstract][Full Text] [Related]
2. Investigation of Suicidality and Psychological Adverse Events in Patients Treated With Finasteride.
Nguyen DD; Marchese M; Cone EB; Paciotti M; Basaria S; Bhojani N; Trinh QD
JAMA Dermatol; 2021 Jan; 157(1):35-42. PubMed ID: 33175100
[TBL] [Abstract][Full Text] [Related]
3. Finasteride Use Is Associated with Higher Odds of Obstructive Sleep Apnea: Results from the US Food and Drug Administration Adverse Events Reporting System.
Gupta MA; Vujcic B; Gupta AK
Skinmed; 2020; 18(3):146-150. PubMed ID: 32790610
[TBL] [Abstract][Full Text] [Related]
4. Persistent Sexual Dysfunction and Suicidal Ideation in Young Men Treated with Low-Dose Finasteride: A Pharmacovigilance Study.
Ali AK; Heran BS; Etminan M
Pharmacotherapy; 2015 Jul; 35(7):687-95. PubMed ID: 26133534
[TBL] [Abstract][Full Text] [Related]
5. Assessing finasteride-associated sexual dysfunction using the FAERS database.
Gupta AK; Carviel J; MacLeod MA; Shear N
J Eur Acad Dermatol Venereol; 2017 Jun; 31(6):1069-1075. PubMed ID: 28300347
[TBL] [Abstract][Full Text] [Related]
6. Are finasteride-related penile curvature/Peyronie's disease Adverse Event Reports worthy of further clinical investigation? Disproportionality analysis based on both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) pharmacovigilance databases.
Schifano N; Capogrosso P; Boeri L; Fallara G; Chiappini S; Rewhorn M; Cakir OO; Harvey H; Castiglione F; Alnajjar HM; Muneer A; Deho' F; Schifano F; Montorsi F; Salonia A
Int J Impot Res; 2023 Aug; 35(5):465-471. PubMed ID: 35513712
[TBL] [Abstract][Full Text] [Related]
7. Safety profiles of adalimumab, etanercept and infliximab: a pharmacovigilance study using a measure of disproportionality in a database of spontaneously reported adverse events.
Mendes D; Alves C; Batel-Marques F
J Clin Pharm Ther; 2014 Jun; 39(3):307-13. PubMed ID: 24635532
[TBL] [Abstract][Full Text] [Related]
8. Alopecia induced by tumour necrosis factor-alpha antagonists: description of 52 cases and disproportionality analysis in a nationwide pharmacovigilance database.
Béné J; Moulis G; Auffret M; Lefevre G; Coquerelle P; Coupe P; Péré P; Gautier S
Rheumatology (Oxford); 2014 Aug; 53(8):1465-9. PubMed ID: 24681837
[TBL] [Abstract][Full Text] [Related]
9. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias.
Pariente A; Gregoire F; Fourrier-Reglat A; Haramburu F; Moore N
Drug Saf; 2007; 30(10):891-8. PubMed ID: 17867726
[TBL] [Abstract][Full Text] [Related]
10. Risk of erectile dysfunction associated with use of 5-α reductase inhibitors for benign prostatic hyperplasia or alopecia: population based studies using the Clinical Practice Research Datalink.
Hagberg KW; Divan HA; Persson R; Nickel JC; Jick SS
BMJ; 2016 Sep; 354():i4823. PubMed ID: 27659058
[TBL] [Abstract][Full Text] [Related]
11. Adverse Events Associated With Radium-223 in Metastatic Prostate Cancer: Disproportionality Analysis of FDA Data Reflecting Worldwide Utilization.
Huynh-Le MP; Shults RC; Connor MJ; Hattangadi-Gluth JA
Clin Genitourin Cancer; 2020 Jun; 18(3):192-200.e2. PubMed ID: 31902714
[TBL] [Abstract][Full Text] [Related]
12. Acute renal failure and cardiac arrhythmias associated with remdesivir use in patients with COVID-19 infections: Analysis using the US FDA adverse event reporting system.
Orogun L; Chyou TY; Nishtala PS
Int J Risk Saf Med; 2023; 34(2):87-99. PubMed ID: 37154187
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumor Necrosis Factor-Alpha Therapy and Hypoglycemia: A Real-World Pharmacovigilance Analysis.
Zhou Y; Xie W; Wang L; Zhu X; Li J; Liu L; Zhu S; Wang L
Drug Saf; 2022 Sep; 45(9):951-959. PubMed ID: 35857191
[TBL] [Abstract][Full Text] [Related]
14. Post-marketing safety concerns with nirmatrelvir: A disproportionality analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System.
Zhuang W; Xu J; Wu Y; Yang J; Lin X; Liao Y; Wan J; Weng L; Lin W
Br J Clin Pharmacol; 2023 Sep; 89(9):2830-2842. PubMed ID: 37170890
[TBL] [Abstract][Full Text] [Related]
15. Cataracts and statins. A disproportionality analysis using data from VigiBase.
Macías Saint-Gerons D; Bosco Cortez F; Jiménez López G; Castro JL; Tabarés-Seisdedos R
Regul Toxicol Pharmacol; 2019 Dec; 109():104509. PubMed ID: 31669197
[TBL] [Abstract][Full Text] [Related]
16. Assessing dutasteride-associated sexual dysfunction using the U.S. Food and Drug Administration Adverse Event Reporting System.
Gupta AK; Carviel J; Gupta MA; Shear NH
J Eur Acad Dermatol Venereol; 2018 Aug; 32(8):1373-1376. PubMed ID: 29194783
[TBL] [Abstract][Full Text] [Related]
17. Adverse Event Reporting in Clinical Trials of Finasteride for Androgenic Alopecia: A Meta-analysis.
Belknap SM; Aslam I; Kiguradze T; Temps WH; Yarnold PR; Cashy J; Brannigan RE; Micali G; Nardone B; West DP
JAMA Dermatol; 2015 Jun; 151(6):600-6. PubMed ID: 25830296
[TBL] [Abstract][Full Text] [Related]
18. Metabolic and Nutritional Disorders Following the Administration of Immune Checkpoint Inhibitors: A Pharmacovigilance Study.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhou X; Zheng Y; Zhao X; Xu X; Cao Y; He J
Front Endocrinol (Lausanne); 2021; 12():809063. PubMed ID: 35145482
[TBL] [Abstract][Full Text] [Related]
19. Skin Toxicities with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Signals from Disproportionality Analysis of the FDA Adverse Event Reporting System.
Raschi E; Fusaroli M; La Placa M; Ardizzoni A; Zamagni C; Poluzzi E; De Ponti F
Am J Clin Dermatol; 2022 Mar; 23(2):247-255. PubMed ID: 34699032
[TBL] [Abstract][Full Text] [Related]
20. A nationwide pharmacovigilance investigation on trends and seriousness of adverse events induced by anti-obesity medication.
Choi YJ; Choi CY; Kim CU; Shin S
J Glob Health; 2023 Sep; 13():04095. PubMed ID: 37651636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
